CANDIDA ACID PROTEINASE AND PATHOGENESIS
CANDIDA ACID PROTEINASE AND PATHOGENESIS
批准号:
2062556
负责人:
THOMAS L RAY
金额:
$16.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-02-01 至 1995-12-31
关键词:
Candida agglutination reaction antifungal antibody antigen antibody reaction candidiasis endopeptidases enzyme linked immunosorbent assay enzyme mechanism fungal genetics gene expression host organism interaction human subject immunofluorescence technique laboratory mouse laboratory rat microorganism culture microorganism immunology nucleic acid sequence phenotype protein biosynthesis serology /serodiagnosis virulence
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Success of Candida as a pathogen may depend partly on high frequency
switching between general phenotypes and their associated expression of
hypothetical sets of virulence genes that in the composite (but not
singularly) facilitate and constitute a strain's pathogenic behavior.
One putative virulence factor, Candida acid proteinase (CAP), is
differentially expressed by switch phenotypes, facilitates pathogenic
behavior, and is a prime candidate for membership in the hypothetical set
of Candida virulence genes. We ask: 1) Do specific switch phenotypes and
their CAP secretion correlate with commensal or pathogenic behavior? 2)
Do patient titers of CAP antibody or antigen correlate with infection,
phenotypes and CAP secretion? 3) Do switch phenotypes and CAP secretion
relate to observed and experimental pathogenic behavior? The project will
determine if switch phenotypes and CAP discriminate between commensal and
pathogenic Candida isolates, and correlate with human and experimental
animal infections.
1. Quantitation of CAP Secretion by Commensal and Pathogenic Candida
Isolates and Phenotypes. Commensal and pathogenic isolates and their
phenotypes from normals and patients with candidiasis, will be obtained.
CAP secretion of each phenotype will be assessed and correlated with 1)
commensal or pathogenic behavior of isolates and switch phenotypes in
patients and 2) the pathogenicity of phenotypes in experimental
candidiasis.
2. CAP Antibody Response and Antigenic Presence in Mucocutaneous and
Systemic Candidiasis. Sera of patients at risk to or with systemic
candidiasis, or with mucocutaneous candidiasis and those with Candida
colonization, will be obtained. CAP antibody and antigen will be
measured by ELISA and latex agglutination. Tissue of infections will be
tested for CAP deposits by immunofluorescent methods. CAP antigen in
sera and tissue and CAP antibody titers will be correlated with clinical
manifestations, the patient's isolate and switch phenotypes and their CAP
secretion. Predictive values of CAP antibody and antigen titers in sera
for infections will be determined. The secretion and presence of CAP in
vivo with be correlated with infecting strains and switch phenotypes.
3. Pathogenicity of Candida Isolates and Their Switch Phenotypes in
Experimental Candidiasis. Virulence of commensal and pathogenic isolates
and switch phenotypes from Candida infections will be tested in murine
models of candidiasis. Virulence will be correlated with isolate
behavior in the patient of, origin, the switch phenotype used, and CAP
secretion. This will demonstrate the role of switch phenotypes and CAP
secretion in experimental infections to compare with clinical infections.
Transitions from commensal to pathogenic phenotypes through switching and
CAP secretion may be elucidated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ROLE OF CANDIDA ACID PROTEINASE IN PATHOGENESIS
-
批准号:3137337
-
项目类别:
-
资助金额:$16.1万
-
财政年份:1988
-
负责人:THOMAS L RAY
-
依托单位:
ROLE OF CANDIDA ACID PROTEINASE IN PATHOGENESIS
-
批准号:3137336
-
项目类别:
-
资助金额:$15.55万
-
财政年份:1988
-
负责人:THOMAS L RAY
-
依托单位:
ROLE OF CANDIDA ACID PROTEINASE IN PATHOGENESIS
-
批准号:3137332
-
项目类别:
-
资助金额:$16.62万
-
财政年份:1988
-
负责人:THOMAS L RAY
-
依托单位:
CANDIDA ACID PROTEINASE AND PATHOGENESIS
-
批准号:2062557
-
项目类别:
-
资助金额:$17.47万
-
财政年份:1988
-
负责人:THOMAS L RAY
-
依托单位:
CANDIDA ACID PROTEINASE AND PATHOGENESIS
-
批准号:3137335
-
项目类别:
-
资助金额:$16.45万
-
财政年份:1988
-
负责人:THOMAS L RAY
-
依托单位: